Free Trial
NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Celldex Therapeutics logo
$21.98 -0.14 (-0.61%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$21.28 -0.70 (-3.16%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Celldex Therapeutics Stock (NASDAQ:CLDX)

Key Stats

Today's Range
$21.67
$22.37
50-Day Range
$18.33
$22.11
52-Week Range
$14.40
$47.00
Volume
978,039 shs
Average Volume
955,997 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.11
Consensus Rating
Moderate Buy

Company Overview

Celldex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

CLDX MarketRank™: 

Celldex Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 1669th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Celldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Celldex Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Celldex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Celldex Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Celldex Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Celldex Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Celldex Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.34% of the float of Celldex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Celldex Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Celldex Therapeutics has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Celldex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Celldex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.34% of the float of Celldex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Celldex Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Celldex Therapeutics has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Celldex Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Celldex Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

CLDX Celldex Therapeutics, Inc. - Seeking Alpha
Elon’s Revenge
Elon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is this: Before he left Washington, Elon Musk left a "parting gift" to folks, which could help you double your money multiple times this year. Everything you need to know is right here.
See More Headlines

CLDX Stock Analysis - Frequently Asked Questions

Celldex Therapeutics' stock was trading at $25.27 at the beginning of the year. Since then, CLDX shares have decreased by 13.0% and is now trading at $21.9750.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.06. The biopharmaceutical company earned $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 2,366.07% and a negative trailing twelve-month return on equity of 23.46%.

Shares of Celldex Therapeutics reverse split on Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLDX
Employees
150
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$50.11
High Stock Price Target
$70.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+128.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$157.86 million
Net Margins
-2,366.07%
Pretax Margin
-2,366.07%

Debt

Sales & Book Value

Annual Sales
$7.02 million
Price / Cash Flow
N/A
Book Value
$11.26 per share
Price / Book
1.95

Miscellaneous

Free Float
63,463,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
1.13

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CLDX) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners